All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
What are the long-term outcomes for patients treated with crenolanib combination therapy?
Featured:
Eunice WangDuring the 2022 ASCO Annual Meeting, the AML Hub spoke with Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the long-term outcomes for patients treated with crenolanib combination therapy.
What are the long-term outcomes for patients treated with cenolanib combination therapy?
Wang presents the long-term outcomes for patients with newly diagnosed FLT3 mutant disease receiving crenolanib (a FLT3 tyrosine kinase inhibitor) and intensive chemotherapy. Wang outlines the study design, efficacy, and safety results of the long-term, multicenter study. Finally, Wang highlights the ongoing phase III trial, which could yield promising results for younger patients treated with potent second-generation FLT3 inhibitors.